10.58
+0.08(+0.76%)
Currency In USD
| Previous Close | 10.5 |
| Open | 10.42 |
| Day High | 10.79 |
| Day Low | 10.08 |
| 52-Week High | 13.6 |
| 52-Week Low | 5.68 |
| Volume | 865,559 |
| Average Volume | 1.15M |
| Market Cap | 625.02M |
| PE | -3.36 |
| EPS | -3.15 |
| Moving Average 50 Days | 8.06 |
| Moving Average 200 Days | 7.94 |
| Change | 0.08 |
If you invested $1000 in Cullinan Therapeutics, Inc. (CGEM) since IPO date, it would be worth $353.73 as of December 04, 2025 at a share price of $10.58. Whereas If you bought $1000 worth of Cullinan Therapeutics, Inc. (CGEM) shares 3 years ago, it would be worth $911.28 as of December 04, 2025 at a share price of $10.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, I
Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
GlobeNewswire Inc.
Nov 10, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune diseases and cancer, today announced its management t
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 2:11 PM GMT
CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status ~30% CRc rate observed at clinically active target doses; initial do